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Abstract
Background: Selective low-density lipoprotein (LDL) apheresis is commonly used to treat patients with familial
hypercholesterolemia (FH). Chemerin is an adipokine with putative roles in the regulation of lipid metabolism.
Methods: In our pilot study, we measured serum chemerin levels by enzyme-linked immunosorbent assay in six
severe heterozygous FH patients before and after their first LDL apheresis treatments using the technique of direct
adsorption of lipoproteins (DALI).
Results: The first treatment sessions decreased serum chemerin levels by an average of 27.26 %. While following
one patient, 12 months of regular LDL apheresis resulted in a permanent reduction in his serum chemerin level.
Changes in the lipoprotein subfractions measured by gel electrophoresis (Lipoprint) correlated with the reduction
of chemerin levels. Furthermore, we eluted and then measured chemerin bound to the DALI column.
Conclusion: We conclude that LDL apheresis decreases the circulating level of chemerin by binding the protein to
the column and thus improves lipoprotein subfraction pattern.
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Background
Familial hypercholesterolemia (FH) is an autosomal
dominant disorder caused most commonly by mutations
in the low-density lipoprotein (LDL) receptor gene lead-
ing to extremely high plasma LDL-cholesterol (LDL-C)
levels and increased risk of premature cardiovascular
disease [1]. Mutations in the genes encoding either apo-
lipoprotein (Apo)B100, proprotein convertase subtilisin/
kexin type 9 (PCSK9) or autosomal recessive hyperchol-
esterolemia adaptor protein also cause FH phenotype
[2]. Although having lower LDL-C and total cholesterol
levels compared to homozygous FH patients, heterozy-
gotes still possess a significantly higher risk of cardiovas-
cular diseases they are left untreated [3]. Homozygous
FH patients are usually resistant to routine lipid lower-
ing therapy and many heterozygous FH patients also do
not respond adequately to these medications.
Selective LDL apheresis is an extracorporeal lipid low-
ering therapy which significantly can reduce the levels of
ApoB-containing particles including LDL, Lipoprotein(a)
(Lp(a)) and very-low-density lipoprotein (VLDL). There-
fore, LDL apheresis is indicated to treat hyperlipidemia
both in homozygous and severe heterozygous FH
patients. Besides lipid lowering, several other beneficial
effects of LDL apheresis have been reported including
anti-atherogenic, anti-thrombotic and anti-inflammatory
actions. As reviewed elsewhere, these lipid lowering
therapies are also reported to reduce the levels of several
pro-inflammatory peptides and cytokines [4].
Secreted from the white adipose tissue, adipo(cyto)kines
play a crucial role in the regulation of lipid and glucose
metabolism. To date, only a few studies examined the
impact of LDL apheresis on adipokine levels. Leitner et al.
reported that serum leptin levels decreased by 42 % after
14 months in a patient on regular LDL apheresis leading
to ravenous hunger and weight gain [5], while Krautbauer
et al. found no changes in serum adiponectin levels after
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LDL apheresis treatment [6]. Resistin and adiponectin
levels were also found to be unaffected by LDL apheresis in
another investigation [7]. Until now, there is no data on the
impact of LDL-apheresis on the serum levels of chemerin.
Chemerin is mainly expressed in white adipose tissue,
liver, kidney, skin and intestine [8], It regulates adipogene-
sis, adipocyte metabolism and lipolysis and controls
adipocyte differentiation as well [9]. Its receptor is also
expressed on different inflammatory cells including mac-
rophages, immature dendritic cells and natural killer cells,
inducing their migration to the site of inflammation [10].
Furthermore, circulating chemerin was reported to par-
ticipate in the regulation of lipid and glucose metabolism
[11]. Therefore, chemerin is considered to be associated
with the development of obesity, insulin resistance and
metabolic syndrome [12]. Although an anti-inflammatory
effect of chemerin was also described [13, 14], there
is a growing evidence that chemerin acts as a pro-
inflammatory peptide [15]. Hence, chemerin may play
a role in atherogenesis.
Previously, we found significant correlations between
serum chemerin levels and lipoprotein subfractions in
nondiabetic obese patients [16]. Circulating chemerin
concentrations correlated positively with LDL-C levels,
while an inverse correlation was found between chemerin
and high-density lipoprotein- (HDL)-cholesterol (HDL-C)
levels. Furthermore, significant positive correlations were
detected between serum chemerin levels and small dense
LDL, intermediate and small HDL subfractions, respect-
ively. On the other hand, negative correlations were ob-
served between chemerin levels and mean LDL size and
large HDL subfraction, respectively. Based on these re-
sults, we concluded that chemerin might have an unfavor-
able effect on lipoprotein metabolism.
We hypothesized that LDL apheresis treatment may
decrease serum chemerin levels that may enhance the
beneficial effect of LDL apheresis on lipid parameters.
Therefore, the aim of this study was to investigate the
short- and long-term effects of selective LDL-apheresis
on serum levels of chemerin in patients with severe het-
erozygous FH. We also measured the chemerin binding
capacity of the columns used for LDL apheresis.
Methods
Patients
We enrolled six patients (three females and three males)
with severe heterozygous FH before their first selective
LDL apheresis treatment.
Characteristics and laboratory parameters before LDL
apheresis are shown in Table 1.
LDL apheresis
LDL apheresis was carried out by direct adsorption of
lipoproteins (DALI) (Fresenius GmbH, Germany), the
DALI 750 adsorber was incorporated in the extracorpor-
eal circuit. DALI primer solution, acid citrate dextrose
formula A (ACD-A) solution, blood lines, and hemadsorp-
tion monitor 4008 ADS (Fresenius HemoCare Adsorber
Technology GmbH, St. Wendel, Germany) were used.
Prior to the session, the adsorbers were rinsed with 3 ×
2000 mL of primer solution at a flow rate of 400 mL/min.
The first 2 L contained 20000 IU of heparin. The
adsorbers were saturated with citrate during priming. The
patient received ACD-A infusion during the session.
ACD-A was first mixed with the patient’s blood at a ratio
of 1:20, which was reduced to 1:40 after 1500 mL of blood
were treated. Two bilateral vascular accesses by vein punc-
ture in the median cubital veins were established. At the
start of the session, the patient was only connected to the
afferent (arterial) line of the extracorporeal circuit. All ses-
sions were carried out under blood pressure monitoring.
Venous blood samples were drawn at the start and at the
end of each session.
Sample collection and laboratory measurements
Serum samples were separated by centrifugation at 4 °C at
3500 g for 10 min. The routine laboratory parameters were
determined from fresh sera with Cobas c501 analyzer
(Roche Ltd. Mannheim, Germany). Total cholesterol levels
Table 1 Patient characteristics and lipid parameters before and
after LDL apheresis
Before treatment After treatment Change in %
Age (years) 60.57 ± 4.79
Gender (female/male) 3/3
Body mass index
(kg/m2)
26.19 ± 2.14
Waist circumference
(cm)
101 ± 8.19
Total cholesterol
(mmol/L)
9.25 ± 1.49 4.41 ± 0.99*** −52.58
LDL-C (mmol/L) 6.92 ± 1.34 2.69 ± 0.97*** −61.84
HDL-C (mmol/L) 1.40 ± 0.31 1.24 ± 0.16* −10.46
Apo B (g/L) 2.10 ± 0.42 0.82 ± 0.28*** −61.49
Apo A (g/L) 1.69 ± 0.19 1.44 ± 0.10** −14.09
Creatinine (μmol/L) 94.33 ± 58.18 82.33 ± 52.95** −13.52
Serum chemerin
(ng/mL)
82.34 ± 36.30 59.09 ± 24.89** −27.26
Large LDL (%) 27.36 ± 6.64 23.72 ± 4.62 −12.20
Small-dense LDL (%) 4.86 ± 4.27 1.14 ± 1.57** −83.81
Mean LDL size (nm) 26.64 ± 0.568 26.98 ± 0.402* 0.129
Large HDL (%) 21.08 ± 4.79 24.36 ± 4.25 16.70
Intermediate HDL (%) 45.16 ± 5.25 50.02 ± 3.47 11.45
Small HDL (%) 33.76 ± 8.66 25.62 ± 5.75** −23.44
Data are presented as mean ± standard deviation (SD). *p < 0.05; **p < 0.01;
***p < 0.001
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were measured by using enzymatic, colorimetric tests
(cholesterol oxidase-p-aminophenazone – GPOD-PAP;
Modular P-800 analyzer; Roche/Hitachi). HDL cholesterol
and LDL cholesterol levels were determined by a
homogenous enzymatic, colorimetric assay (Roche HDL-C
plus 3rd generation and Roche LDL-C plus 2nd generation,
respectively). Apo A-I, ApoB and Lp(a) examinations were
performed by immunoturbidimetric assays (Tina-quant
apolipoprotein A-I ver. 2, Tina-quant apolipoprotein B ver.
2 and Tina-quant lipoprotein(a) ver. 2, respectively). The
tests were performed according to the recommendation of
the manufacturer. Sera were kept frozen at −70 °C for
subsequent lipoprotein subfraction analysis and ELISA
measurements.
Chemerin elution
We eluted chemerin from the apheresis column on the
basis of the modified method of Dihazi et al. [17]. At the
end of the session, DALI 750 columns were washed with
phosphate-buffered saline (PBS) buffer of pH 7.4. Pro-
tein elution was carried out in a three-step elution
process using 250 mL each of three acetate buffer solu-
tions of different pH, in the following order: pH 5.0,
pH 4.0, pH 3.0.
LDL subfraction analysis
LDL subfractions were detected by an electrophoretic
method on polyacrylamide gel using the Lipoprint
System (Quantimetrix Corp., Redondo Beach, CA, USA),
according to the manufacturer’s instructions. 25 μL of
serum samples were added to polyacrylamide gel tubes
along with 200 μL a loading gel solution containing
Sudan Black as a lipophilic dye. The sample loading gel
mixture was photopolymerized for 30 min at room
temperature prior to electrophoresis at a constant of
3 mA/tube for one hour. Each electrophoresis chamber
contained a quality control, which was provided by the
manufacturer (Liposure Serum Lipoprotein Control;
Quantimetrix Corp., Redondo Beach, CA, USA). For
quantification, scanning was performed with an ArtixScan
M1 digital scanner (Microtek International Inc., Santa Fe
Springs, CA). Lipoprotein fractions (bands) were identified
after electrophoresis by their mobility (Rf) using VLDL as
the reference point (Rf 0.0) and HDL as the ending refer-
ence point (Rf 1.0). In between, LDL subfractions were
distributed starting from LDL 1 to LDL7 (Rf 0.32, 0.38,
0.45, 0.51, 0.56, 0.6 and 0.64, respectively). LDL1 and
LDL2 bands correspond to large buoyant LDL subclasses,
whereas LDL3-7 bands correspond to small dense LDL
subclasses. The percentages of the area under the curve
(AUC%) for the VLDL, intermediate-density lipoprotein
(IDL), LDL (maximum 7 subfractions), and HDL
peaks were calculated with Lipoware computer soft-
ware (Quantimetrix Corp., Redondo Beach, CA, USA).
Proportion of large LDL (large LDL %) was defined as the
sum of the percentage of LDL1 and LDL2, whereas pro-
portion of small LDL (small LDL %) was defined as the
sum of LDL3- LDL7. Mean LDL size (nm) was also calcu-
lated by the Lipoware software.
HDL subfraction analysis
High density lipoprotein subfractions were also detected
by Lipoprint, according to the manufacturer’s instructions.
Briefly, 25 μL of serum sample was added to polyacryl-
amide gel tubes along with 300 μL of a loading gel solu-
tion containing Sudan Black as a lipophilic dye. After
30 min of photopolimerization at room temperature, elec-
trophoresis was performed for 50 min with 3 mA/tube.
Each electrophoresis chamber contained a quality control,
which provided by the same manufacturer. Stained HDL
subfractions (bands) were identified by their electrophor-
etic mobility. LDL/VLDL band was used as the starting
reference point (Rf 0.0), while albumin served as the end-
ing reference point (Rf 1.0). AUC% was calculated with the
Lipoware computer software. Distributed between the ref-
erence points, HDL subfractions were grouped into three
major classes: large (HDL1-HDL3), intermediate (HDL4-
HDL7) and small (HDL8-HDL10) HDL subfractions.
Serum chemerin concentration measurement
Serum chemerin concentrations were measured by a
commercially available ELISA kit (Human Chemerin
Quantikine ELISA, cat. number: DCHM00, R&D Systems,
MN, USA), according to the recommendations of the
manufacturer. The intra- and interassay coefficients of
variations were <10 % and <12 %, respectively.
Determination of chemerin concentration in eluted
solution
Chemerin concentrations of the eluted solutions were
measured by a commercially available ELISA kit (Human
Chemerin DuoSet ELISA, cat. number: DY2324, R&D
Systems, MN, USA).
Statistical methods
Statistical analyses were performed by STATISTICA
(version 6.0) (Statsoft Inc., Tulsa, OK, USA) and IBM
Statistical Package for the Social Sciences (SPSS) Statistics
(version 19) (IBM Corp., Armonk, NY, USA) computer
softwares. Normality of distribution was tested by
Kolmogorov-Smirnov test and data were analyzed with
paired t test. Data were expressed as means ± standard
deviation (SD) or median (upper quartile-lower quartile).
A value of P < 0.05 was considered to be statistically
significant. Friedman-ANOVA and Kendall Coeff. of con-
cordance test was used to compare eluted chemerin con-
centrations using solution buffers of various pH.
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Results
Anthropometric and laboratory characteristics of the
study participants are summarized in Table 1. After the
first LDL apheresis, serum chemerin levels significantly
decreased in all patients, on the average by 27.26 %
(from the mean of 82.34 ng/mL to 59.09 ng/mL). To ex-
clude the effect of dilution caused by the treatment we
also calculated the serum chemerin/creatinine ratios,
which also showed a significant decrease of 16.65 % after
the first sessions. Reductions in individual serum che-
merin levels and chemerin/creatinine ratios are shown
in Fig. 1.
In order to examine the long-term effect of LDL
apheresis on serum chemerin concentrations, we
followed the serum chemerin levels of patient 2 (P2,
selected randomly) before and after 10 LDL apheresis
sessions. We found that chemerin levels showed a
decreasing tendency during this 12-month follow-up. It
has to be mentioned that the patient asked to suspend
the apheresis for 3 months after the fifth session. After
this period, we observed a marked increase in the circu-
lating level reaching its initial value. Notably, serum che-
merin concentration started to decrease after restarting
LDL apheresis, indicating the importance of continuous
treatment to maintain permanent reduction of serum
chemerin levels (Fig. 2).
To prove that chemerin physically binds to the column,
we eluted protein fractions from the apheresis column
with three different acetate buffer solutions of different
pH. The chemerin concentrations of the different solu-
tions are shown in Table 2. Significantly more protein was
eluted by buffer solutions of higher pH (p < 0.01).
Using Lipoprint, plasma LDL and HDL subfractions
of selected cases were also measured before and after
LDL apheresis sessions. After treatment, favorable
quantitative and qualitative changes in LDL and HDL
subfractions were observed (Table 1). Among these,
LDL apheresis markedly reduced the small dense LDL
subfractions (Table 1 and Fig. 3).
Discussion
Concordant with previous data, selective LDL apheresis
reduced LDL-C and Lp(a) levels in patients with FH. Add-
itionally, LDL apheresis confers other pleiotropic effects
protecting patients against atherosclerosis as it decreases
the plasma concentrations of several pro-inflammatory
markers including cytokines, chemokines, adhesion fac-
tors and C-reactive protein, too [4]. Although the mecha-
nisms of these changes are still unknown, both direct
binding and indirect changes via altered gene transcription
and translation are suggested. Dihazi et al. compared
serum samples by proteomic analysis before and after
LDL apheresis [17] and they found significant depletion of
more than 70 functional proteins including peptides that
were involved in the coagulation system and that with ad-
hesive, rheological and inflammatory actions. They con-
cluded that there was a strong interaction between the
column and serum proteins during treatment, while
others found altered gene expression of various molecules
after the apheresis [18–20].
To the best of our knowledge, the impact of LDL apher-
esis on serum chemerin level has not been investigated
Fig. 1 a Serum chemerin levels of the six patients (P1-P6) in ng/mL
and; b Serum chemerin/creatinine ratios of the six patients (P1-P6) in
% immediately before and after their first selective LDL apheresis
sessions using DALI 750 columns. Abbreviation: SEM, standard error
of the mean
Fig. 2 Changes in serum chemerin levels of a patient (P2) measured
before LDL apheresis sessions during a 12-month period. Treatment
has been suspended for three months (labelled with dotted line)
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yet. In our study, we found that serum chemerin levels
decreased markedly after selective LDL apheresis in FH
patients. We also demonstrated – although only in one
patient - that continuous treatment was necessary to
maintain lower serum chemerin levels. Besides decreasing
LDL-C levels, lowering the circulating chemerin concen-
trations may be an additional beneficial effect of LDL
apheresis, due to the suggested pro-inflammatory and pro-
atherogenic properties of chemerin. Since LDL apheresis is
currently not a widely used method in the treatment of
severe hyperlipidemias, we had a limited patient number.
Therefore, further studies on larger patient populations
are needed to prove the short- and long-term effects of se-
lective LDL apheresis on serum chemerin levels.
After the treatment sessions, we could elute a signifi-
cant amount of chemerin from the apheresis column;
supporting the data that chemerin might physically bind
to the apheresis column; however the exact mechanism
of this binding is unknown. Although there is no infor-
mation in the literature about the charge of chemerin,
Table 2 Chemerin levels of solution eluted from the LDL apheresis column in ng/mL
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Average
pH 3.0 148.89 79.73 71.69 134.69 37.82 24.77 75.7 (37.8–134.7)
pH 4.0 383.28 187.44 169.43 112.59 122.23 124.62 147.0 (122.2–187.4)
pH 5.0 649.73 272.62 273.76 176.37 188.79 278.31 273.2 (188.8–278.3)
Fig. 3 Representative lipoprotein subfraction patterns, before (a) and (b) after LDL apheresis in a patient with familial hypercholesterolemia. Small
dense LDL subfractions are shown in red
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one may speculate that it could bind to the column
directly, similarly to the positively charged ApoB100-
containing lipoprotein particles. On the other hand, it is
also possible that chemerin might be associated to the
positively charged lipoprotein particles and therefore it
binds indirectly to the adsorber column. Further studies
are needed to explore the exact mechanism.
Previous studies demonstrated that LDL apheresis re-
sults in a decrease of the small dense, particularly pro-
atherogenic LDL subfraction and it also modifies sub-
fraction pattern into a more anti-atherogenic manner
[21, 22]. In our study, we found that LDL subfractions
changed favorably both in terms of quantity and propor-
tions after apheresis, yielding a marked reduction in the
small dense and highly atherogenic LDL subfractions.
These subfractions possess an increased susceptibility
for oxidative modification; therefore play a key role in
the initiation and progression of atherosclerosis. Hence,
reduction of these subfractions is of major importance
in this high-risk population. Based upon our results, the
efficacy of the treatment on lipid subfractions may also
correlate with its chemerin lowering effect.
Conclusions
To date, this is the first, although pilot, study on the im-
pact of LDL apheresis on circulating chemerin levels.
We also demonstrated that the chemerin lowering effect
can be explained by the binding of the protein to the ad-
sorber column during LDL apheresis. Further studies are
needed to clarify the associations between the changes
in the serum chemerin levels and the impact of LDL
apheresis on lipid subfractions and their long-term asso-
ciations with the atherosclerotic process. The better un-
derstanding of the pleiotropic, non-lipid effects of LDL
apheresis may alter our therapeutic strategy in patients
with severe hypercholesterolemia and may contribute to
maximize the cardiovascular risk reduction in this
patient population.
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